Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Santen Pharmaceutical Co., Ltd.8 enrolled

Overview

To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Adult Males Volunteers

Interventions

STN1012600 ophthalmic solution 0.002%DRUG

1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days

Eligibility

Sex: MALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol Exclusion Criteria: * Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective * Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator

Locations (1)

Medical Corporation Heishinkai OPHAC Hospital

Osaka, Japan

Outcomes

Primary Outcomes

Maximum Plasma Concentration [Cmax]

Calculate plasma pharmacokinetic parameters and study pharmacokinetics.

Time frame: 1 week, Day 1 and Day 7

Secondary Outcomes

Area Under The Curve From Time Zero to the Last Sampling Time [AUC 0-t]

Calculate plasma pharmacokinetic parameters and study pharmacokinetics.

Time frame: 1 week, Day 1 and Day 7

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.